Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China.

This study assessed the cost-effectiveness of encorafenib plus cetuximab (EC) and EC combined with mFOLFOX6 versus standard of care (SOC) as first-line treatment for BRAF V600E-mutant metastatic colorectal cancer from a Chinese healthcare perspective. Using a partitioned survival model with data from the BREAKWATER trial, we found that compared to SOC, the incremental cost-effectiveness ratios for EC and EC plus mFOLFOX6 were 77,589.95 per quality-adjusted life year (QALY) and 82,419.06 per QALY, respectively, both exceeding the willingness-to-pay threshold of $40,343.68/QALY.

At this threshold, SOC had a 95.43% probability of being cost-effective against EC, and 99.64% against EC plus mFOLFOX6. We conclude that neither EC nor EC plus mFOLFOX6 is cost-effective in China at current prices, suggesting the price negotiations would be necessary to improve their economic value.